BioWorld Asia

March 17, 2010

View Archived Issues

Ablynx Growing Post-IPO, Adds $68M to Advance Nanobodies

A Glimpse of the Microbial Genomes Inside our Guts

€13M Restocks Antisense Coffers for Cancer Drug Trial

No Abstract Read More

Kuros Achieves First Proof in Repairing Bone Fractures

Immunotherapy Still an 'Option,' Transgene-Novartis Deal Proves

Rhythm Hits Stride, Raises $21M in Series A for Phase I Peptides

Other News To Note

Sans Partner, Oxford BioMedica Restarting TroVax Development

LONDON - Oxford BioMedica plc is restarting clinical development of its TroVax cancer immunotherapy 12 months after the failure of a Phase III trial in renal cancer led partner Sanofi-Aventis SA to drop the product. (BioWorld International) Read More

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...